Ratifi Español Sign in
Ratifi

Federal bills from Congress.gov. State bills from Open States.

SB 706Session 2026

What changed between versions

16 paragraphs changed+31 words added−14 removed

Highlighted text was added in the newer version. Struck-through text was removed.

2026 SESSION

ENROLLEDINTRODUCED

VIRGINIA ACTS OF ASSEMBLY -- CHAPTER

26103585D

SENATE BILL NO. 706

Offered January 14, 2026

Prefiled January 14, 2026

AnA ActBILL to amend the Code of Virginia by adding a section numbered 32.1-45.5, relating to Department of Health; opioid antagonist distribution program; reports.

[S 706]

Approved

—————

Patron—Srinivasan

—————

Referred to Committee on Education and Health

—————

Be it enacted by the General Assembly of Virginia:

1. That the Code of Virginia is amended by adding a section numbered 32.1-45.5 as follows:

§ 32.1-45.5. Opioid antagonist distribution program; reports.

A. The Department shall maintain a list of all agencies and organizations that submit requests for and receive opioid antagonists through its distribution program. At least quarterly, the DepartmentD epartment shall submit a report to the Chairs of the House Appropriations Subcommittee on Health and Human Resources, House Health and Human Services Committee, Senate Finance and Appropriations Subcommittee on Health and Human Resources, and Senate Subcommittee on Health and the chairc hair of the Virginia Opioid Abatement Authority with the following information: (i) the name of the agency or organization; (ii) the county, city, or town service area; (iii) the quantity, along with the specific formulation and dosage of opioid antagonist, requested by the agency or organization in its most recent order, and the date the request was made; and (iv) the quantity, along with the specific formulation and dosage of opioid antagonist, received by the agency or organization in response to its most recent order, and the date the request was fulfilled.

B. The Department shall develop a methodology to estimate annual opioid antagonist distribution program costs. In developing such methodology, the Department shall use available data and consider account saturation goals, community needs, local resources, and the costs of products. The Department shall submitsubmi t an annual report estimating the opioid antagonist distribution program costs for the following fiscal year using such methodology to the Joint Commission on Health Care and the Chairs of the House Appropriations Committee and the Senate Finance and Appropriations Committee by December 1 of each year.

Back to the full text